How tumors caused by STD quickly regress in dogs

April 09, 2018

The canine transmissible venereal tumor is a contagious cancer that has spread by mating among dogs worldwide. One unique feature of this cancer is that, for unclear reasons, it regresses spontaneously or a few weeks after a single treatment of radiotherapy or chemotherapy. A study published April 9 in the journal Cancer Cell shines a light on this mystery, revealing a key role for the immune system in triggering fast cancer rejection in chemotherapy-treated dogs. Because the canine transmissible venereal tumor shares many similarities with various human cancers, the findings could point to more effective therapeutic strategies.

"We found that activation of the innate immune system and production of certain molecules called chemokines by the host tissue around the tumor is critical to attract immune cells within the tumor and trigger a chain reaction that leads to the rejection of the cancer and its elimination," says senior author Professor Ariberto Fassati of UCL (University College London). "We hope that this study will encourage the clinical testing of combined approaches to improve immunological therapies against cancer, in animals and humans alike."

First described in the 1800s, the canine transmissible venereal tumor rapidly grows into a cauliflower-like mass on genitalia, and it is naturally transmitted between dogs by coitus, biting, or licking tumor-affected areas. It is one of three known clonally transmissible cancers in nature, along with Tasmanian devil facial disease and leukemias in soft-shell clams. Because it originated from a single common ancestor, the canine transmissible venereal tumor consists of genetically identical cells in all affected dogs, making it easier to identify key factors driving cancer regression. Yet few labs have investigated this topic, leaving it unclear how cancer rejection occurs.

To answer this question, Fassati and his collaborators collected biopsies from canine transmissible venereal tumors in eight dogs before treatment as well as 6 days and 14 days after receiving a chemotherapy drug called vincristine. The researchers performed systematic genome-wide analyses to compare gene activity in tumors that fully regressed with those that did not regress.

They discovered that regression occurs in sequential steps. First, vincristine treatment led to a strong inflammatory response and the proliferation of host skin cells, which may represent an attempt by the tissue surrounding tumors to contain or replace the malignant tissue. "We were expecting that most changes leading to regression of this dog tumor would occur in the cancer cells," Fassati says. "Instead, we realized that the host cells were more important."

This early stage of regression was also characterized by an increase in the production of a chemokine called CCL5--a signaling protein that attracted cancer-fighting immune cells to the tumor. Ultimately, this process resulted in immune rejection of the tumor and repair of tissue damage.

"There are two key messages of our study," Fassati says. "First, we should not focus on the cancer cells only but also understand the importance of normal tissue around the cancer in promoting rejection. Second, we must be able to induce the production of large amounts of certain chemokines to attract loads of immune cells to the tumor site."

In the end, this research could have implications for human cancers, such as skin cancer, bone cancer, and certain blood cancers. For his own part, Fassati plans to investigate whether it's possible to stimulate chemokines that attract immune cells to tumors in human cancers. "However, it may take some time before these approaches are tested in the clinic," he says. "So the general audience should not take away the message that we have found the magic wand to make cancer disappear."

Despite these limitations, this research could help guide ongoing and future clinical investigations. "There might be ways to improve the efficacy of immunological therapies against cancer by combining different approaches, such as releasing the breaks of the immune system through checkpoint inhibitors and inducing host cells surrounding the tumor to attract the unleashed immune cells to the tumor site," Fassati says. "Indeed, there are already ongoing trials that combine low-dose radiotherapy or chemotherapy with immunological therapies, precisely to stimulate a strong inflammatory response in the tumor."
-end-
This study was funded by a grant from the UCL Cancer Center Development Fund and the Biotechnology and Biological Sciences Research Council. Additional support was received by the Wellcome Trust and the UK Medical Research Council.

Cancer Cell, Frampton et al.: "Molecular Signatures of Regression of the Canine Transmissible Venereal Tumor" http://www.cell.com/cancer-cell/fulltext/S1535-6108(18)30071-0

Cancer Cell (@Cancer_Cell), published by Cell Press, is a monthly journal that provides a high-profile forum to promote major advances in cancer research and oncology. The journal covers topics related to molecular and cellular mechanisms of cancer, mechanisms for the sensitivity and the resistance to cancer therapies, development of better cancer therapies, and clinical investigations. Visit: http://www.cell.com/cancer-cell. To receive Cell Press media alerts, contact press@cell.com.

Cell Press

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.